Zheng Cheng Yi Pharmaceutical Co., Ltd. is a comprehensive modern pharmaceutical enterprise specializing in the production of capsules, injections, tablets, raw materials, and pharmaceutical intermediates. It is one of the top 100 chemical pharmaceutical enterprises in China and the first listed marine biopharmaceutical company in the province. The company has always been committed to the research and development of marine biopharmaceuticals, focusing on product research and development breakthroughs and business model innovation, and continuously expanding market share. In 2019, the operating revenue of the pharmaceutical and pharmaceutical business was 680 million yuan, a year-on-year increase of 25.2%. In the first quarter of this year, the operating revenue was 136 million yuan, and the company's net profit increased by 13.4% year-on-year.
1、 Cultivate a "health industrial park" to enhance the productivity of enterprise development
Taking marine biopharmaceuticals, traditional Chinese medicine, and other industries as the main development directions, we will invest 500 million yuan to build the first phase of the health industry park project, forming a complete industrial chain and radiating the transformation and upgrading of the marine health industry. At present, the project has been basically completed and is undergoing trial production, and has been listed as the second batch of major industrial projects in Zhejiang Province by the Development and Reform Commission and the Provincial Department of Natural Resources. The enterprise also invested 600 million yuan to build the second phase of the health industry park project, implementing an annual production of 1000 tons of super fish oil EPA and traditional Chinese medicine projects, with an estimated annual sales revenue of about 2 billion yuan and tax revenue of about 300 million yuan.
2、 Establishing an "Academician Think Tank" to Improve the Competitiveness of Technology Research and Development
Establish innovative research and development platforms such as the "Provincial Cheng Yi Medical Health Research Institute" and the "Cheng Yi Wenzhou Medical University New Drug Research Institute" to maintain corporate competitiveness. Taking advantage of the opportunity of being awarded as a "provincial-level enterprise research institute" by the "Cheng Yi Pharmaceutical Health Research Institute", we have jointly established the "Academician Expert Workstation" with Academician Ding Jian of the Chinese Academy of Sciences, committed to developing targeted anti-tumor drugs with a single variety sales revenue of over 1 billion yuan. At present, Cheng Yi Pharmaceutical has 12 invention patents, led the formulation of 6 national drug standards, participated in 5 projects, and has more than 20 new products under development.
3、 Weave a dense "three-dimensional marketing network" to expand the brand influence of enterprises
Adopting direct sales and distribution models, continuously expanding sales channels and expanding sales networks. Maintain good cooperative relationships with 153 suppliers including Gaoji Pharmaceutical, National University Pharmacy, People's Daily, and Yifeng Pharmacy. As the only pharmaceutical enterprise in China that has simultaneously accepted and passed the joint GMP audits of the US FDA, Australian TGA, EU EMEA, and Singapore HAS, it has undergone a total of 7 domestic and foreign GMP audits, 17 customer quality audits, and ESH audits since last year, all of which have passed smoothly. Relying on excellent products, the enterprise actively expands overseas markets, establishes an International marketing center in Shanghai Hongqiao, builds a marketing team, and establishes a global marketing network.
4、 Strengthen the sense of social responsibility and enhance the infectivity of corporate culture
While committed to personal development, actively fulfilling social responsibilities. In the face of the COVID-19, the company urgently recalled local employees on leave on the third day of the New Year's Day to work overtime to produce ribavirin injections and capsules. The drug was included in the fifth and sixth editions of the National Diagnosis and Treatment Plan for novel coronavirus Infection Pneumonia. The enterprise took advantage of its resource accumulation and technical advantages in the pharmaceutical industry to deeply participate in the prevention and control of the COVID-19, and donated more than 1 million yuan of various anti epidemic materials.